This systematic review evaluates secondary malignancies from tyrosine kinase inhibitors in patients with chronic myeloid leukemia, comparing risks associated with different TKI agents.
Key Points
The review aims to assess the incidence of secondary malignancies in chronic myeloid leukemia patients undergoing TKI therapy.
Conflicting evidence from observational studies highlights concerns over long-term adverse events of tyrosine kinase inhibitors.
Multiple databases will be searched to synthesize available data regarding risks associated with tyrosine kinase inhibitors.
The findings of this systematic review will address ongoing safety concerns of tyrosine kinase inhibitors for CML treatment.